The most prominent clinical syndrome associated with a disordered hypersecretion of Calcitonin is medullary carcinoma of the thyroid (MTC). MTC is a tumor of the Calcitonin producing C-cells of the thyroid gland. Although MTC is rare, comprising 5 - 10% of all thyroid cancer, it is often fatal. It may occur sporadically or in a familial form that is transmitted as an autosomal dominant trait. MTC has great clinical importance because of its familial distribution. Further, it leant itself to be diagnosed early by serum Calcitonin and total cure for early sub-clinical disease is possible1. This is frequently associated with other clinical features and it has good potential for cure with surgery. Although a rare tumor, it can occur in a familial pattern1 as a Type II multiple endocrine neoplasia.

Human Anti-cyclic citrullinated peptide antibody (CCP-Ab) ELISA Kit has been pre-coated with an antibody specific to CCP-Ab. Standards or samples are then added to the appropriate microtiter plate wells with a Horseradish Peroxidase (HRP)-conjugated CCP-Ab and incubated. The competitive inhibition reaction is launched between with HRP labeled CCP-Ab and unlabeled CCP-Ab with the antibody. A substrate solution is added to the wells and the color develops in opposite to the amount of CCP-Ab in the sample. The color development is stopped and the intensity of the color is measured.

Human Anti-cyclic citrullinated peptide antibody (CCP-Ab) ELISA Kit listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Find more details at http://www.abbkine.com/product/human-anti-cyclic-citrullinated-peptide-antibody-ccp-ab-elisa-kit-kte62460/

Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.